Starling Oncology
STLN
21 hedge funds and large institutions have $200M invested in Starling Oncology in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 42 closing their positions.
9% less capital invested
Capital invested by funds: $219M → $200M (-$19.3M)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
59% less funds holding
Funds holding: 51 → 21 (-30)
67.64% less ownership
Funds ownership: 95.95% → 28.31% (-68%)
69% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$107M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$22.2M |
| 3 |
PGM
Parian Global Management
Pound Ridge,
New York
|
+$4.15M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.93M |
| 5 |
AGM
Alpine Global Management
New York
|
+$3.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$15.7M |
| 2 |
DM
Deerfield Management
New York
|
-$15.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$12.7M |
| 4 |
DKCM
Davidson Kempner Capital Management
New York
|
-$12.6M |
| 5 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$12.3M |
STLN Hedge Fund Activity: Q4 2021 in Review
21 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology (STLN) for Q4 2021, worth a combined $200M — down 8.8% from $219M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of STLN and 13 opened new positions — a net loss of 29 holders — while 5 trimmed existing stakes and 3 added.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $107M. The largest seller was Millennium Management, exiting entirely with an estimated $15.7M sold.
- 21 institutional investors held Starling Oncology (STLN) as of Q4 2021, down from 51 in Q3 2021.
- Funds reported $200M of Starling Oncology stock for Q4 2021, down 8.8% quarter-over-quarter.
- 13 funds opened new Starling Oncology positions in Q4 2021 and 42 closed out, a net change of -29 holders.
- The largest Starling Oncology buyer in Q4 2021 was Fidelity Investments, an estimated $107M added.
- The largest Starling Oncology seller in Q4 2021 was Millennium Management, an estimated $15.7M sold.
Based on aggregated 13F filings for Q4 2021.